Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 76
- Registration Number
- NCT01523860
- Locations
- 🇮🇹
Oncologia Medica ed Ematologia, Istituto Clinica Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Forlì-Cesena, Italy
🇮🇹UO Oncologia ed Onco-Ematologia, Ospedale di Rimini, Rimini, Rn, Italy
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
- Conditions
- Hodgkin's Lymphoma
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2013-03-06
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 495
- Registration Number
- NCT01478191
- Locations
- 🇮🇹
A.O. di Padova Divisione di Oncologia Medica, Padova, Italy
🇮🇹Divisione di Ematologia Osp.Businco, Cagliari, Italy
🇮🇹Istituto Oncologico del Mediterraneo, Catania, Italy
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
- Conditions
- B-Cell Lymphomas
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 1927
- Registration Number
- NCT01478269
- Locations
- 🇧🇷
Hemocentro-Unicamp, Campinas, Brazil
🇧🇷Centro Paulista de Oncologia, Sao Paolo, Brazil
🇮🇹Centro Oncologico Modenese, Modena, Italy
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
- Conditions
- Elderly Patients (>65 Years)Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 226
- Registration Number
- NCT01148446
- Locations
- 🇮🇹
Ospedale San Sebastiano, Correggio (RE), Italy
🇮🇹Istituto Vito Fazzi, Lecce, Italy
🇮🇹S.C. di Ematologia, Spedali Civili, Brescia, Italy
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 50
- Registration Number
- NCT01009970
- Locations
- 🇮🇹
Ospedale Sant'Eugenio, Roma, Italy
🇮🇹Ospedale Riuniti, Trieste, Italy
🇮🇹Ospedale SS Antonio Biagio e Cesare Arrigo, Alessandria, Italy
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
- Conditions
- Non Hodgkin LymphomaFollicular Lymphoma
- Interventions
- Drug: LR-CHOP21
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 49
- Registration Number
- NCT00907348
- Locations
- 🇮🇹
Istituto di Ematologia "Seragnoli" Polic.S.Orsola-Malpighi, Bologna, Italy
🇮🇹Divisione di Ematologia Osp. Businco, Cagliari, Italy
🇮🇹UO Ematologia II Facoltà di Medicina e Chirurgia Università Federico II, Napoli, Italy
Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters
- Conditions
- Lymphoblastic Lymphoma
- Interventions
- Other: Latest generation chemotherapies for T-LBL + transplant
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 100
- Registration Number
- NCT00882011
- Locations
- 🇮🇹
Casa Sollievo della Sofferenza, Foggia, Italy
🇮🇹Azienda Ospedaliera Papardo, Messina, Italy
🇮🇹Policlinico San Matteo, Pavia, Italy
Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory
- Conditions
- Hodgkin's Lymphoma
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 264
- Registration Number
- NCT00879528
- Locations
- 🇮🇹
Dipartimento di Oncologia Medica ed Ematologia Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Div Ematologia A.O. Bianchi - Melacrino - Morelli, Reggio Calabria, RC, Italy
🇮🇹Ematologia Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 33
- Registration Number
- NCT00786851
- Locations
- 🇮🇹
Centro diriferimento oncologico, Aviano (PN), Italy
🇮🇹Ematologia Ospedale Businco, Cagliari, Italy
🇮🇹AO Bianchi Melacrino Morelli UO Ematologia, Reggio Calabria, Italy
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients
- Conditions
- Hodgkin's Lymphoma
- Interventions
- Drug: ABVDDrug: ABVD and Radiotherapy
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 520
- Registration Number
- NCT00784537
- Locations
- 🇮🇹
Sezione di Ematologia Spedali Civili, Brescia, Italy
🇮🇹Policlinco Sant'Orsola Isituto di Ematologia ed oncologia Medica, Bologna, Italy
🇮🇹Università Policlinico di Bari - Divisione di Medicina A, Bari, Italy